Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement
Advanced Science · 2024-11 · 11 (42)
DOI: 10.1002/advs.202406656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.09.2024. Verfasst von Sen Luo und 21 weiteren Autor:innen. Beteiligte Einrichtung: The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, …. Hauptthemen laut MEDLINE: Spider Venoms, NAV1.7 Voltage-Gated Sodium Channel, Analgesics, Disease Models, Animal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, The Scientific Research Program of FuRong Laboratory, The open research fund of Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control.
Abstract (Originalsprache)
The inhibition of Nav1.7 is a promising strategy for the development of analgesic treatments. Spider venom‐derived peptide toxins are recognized as significant sources of Nav1.7 inhibitors. However, their development has been impeded by limited selectivity. In this study, eight peptide toxins from three distinct spider venom Nav channel families demonstrated robust inhibition of hNav1.7, rKv4.2, and rKv4.3 (rKv4.2/4.3) currents, exhibiting a similar mode of action. The analysis of structure and function relationship revealed a significant overlap in the pharmacophore responsible for inhibiting hNav1.7 and rKv4.2 by HNTX‐III, although Lys25 seems to play a more pivotal role in the inhibition of rKv4.2/4.3. Pharmacophore‐guided rational design is employed for the development of an mGpTx1 analogue, mGpTx1‐SA, which retains its inhibition of hNav1.7 while significantly reducing its inhibition of rKv4.2/4.3 and eliminating cardiotoxicity. Moreover, mGpTx1‐SA demonstrates potent analgesic effects in both inflammatory and neuropathic pain models, accompanied by an improved in vivo safety profile. The results suggest that off‐target inhibition of rKv4.2/4.3 by specific spider peptide toxins targeting hNav1.7 may arise from a conserved binding motif. This insight promises to facilitate the design of hNav1.7‐specific analgesics, aimed at minimizing rKv4.2/4.3 inhibition and associated toxicity, thereby enhancing their suitability for therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, 410081, China.
- Peptide and small molecule drug R&D platform, Furong Laboratory, Hunan Normal University, Changsha, Hunan, 410081, China.
- Institute of Interdisciplinary Studies, Hunan Normal University, Changsha, 410081, China.
- Henan Academy of Innovations in Medical science, Institute of Electrophysiology, Zhengzhou, Henan, 450000, China.
- Key Laboratory of Hunan Province for Advanced Carbon-based Functional Materials, School of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang, Hunan, 414006, China.
- Department of Research, Scope Research Institute of Electrophysiology, Kaifeng, 475004, China.
ORCID-Profile: Zhonghua Liu
Förderung
- The National Natural Science Foundation of China
- The Scientific Research Program of FuRong Laboratory
- The open research fund of Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control
- The Hunan Provincial Natural Science Foundation of China
- The Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Luo, S., Zhou, X., Wu, M., Wang, G., Wang, L., Feng, X., Wu, H., Luo, R., Lu, M., Ju, J., Wang, W., Yuan, L., Luo, X., Peng, D., Yang, L., Zhang, Q., Chen, M., Liang, S., Dong, X., …, & Liu, Z. (2024). Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement. Advanced Science, 11(42). https://doi.org/10.1002/advs.202406656
Vancouver
Luo S, Zhou X, Wu M, Wang G, Wang L, Feng X, et al. Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement. Advanced Science. 2024;11(42). doi:10.1002/advs.202406656
BibTeX
@article{Luo2024,
author = {Luo, Sen and Zhou, Xi and Wu, Meijing and Wang, Gongxin and Wang, Li and Feng, Xujun and Wu, Hang and Luo, Ren and Lu, Minjuan and Ju, Junxian and Wang, Wenxing and Yuan, Lei and Luo, Xiaoqing and Peng, Dezheng and Yang, Li and Zhang, Qingfeng and Chen, Minzhi and Liang, Songping and Dong, Xiuming and Hao, Guoliang and Zhang, Yunxiao and Liu, Zhonghua},
title = {Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {42},
doi = {10.1002/advs.202406656}
}
EUVIMED